Jupiter Neurosciences, Inc. JUNS 深 沪
等待开盘 04-01 09:30:00 美东时间
0.3762
+0.051
+15.83%
华盛通- 最 高0.3762
- 今 开0.338
- 成交量 3.22万股
- 最 低 0.318
- 昨 收 0.3248
- 总市值 1295.12万
- 52周最高 3.33
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 0.3062
- 委 比 0.00%
- 总股本 3442.64万
- 历史最高 19.51
- 量 比 0.28
- 振 幅 17.92%
- 历史最低 0.3062
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
Jupiter Neurosciences, Inc. has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026. The company will showcase JOTROL™, its patented resveratrol-based platform, which powers its therapeutic and consumer longevity products. Jupiter is developing treatments for CNS disorders and rare diseases while expanding its Nugevia™ product line for healthy aging. The presentation will be available...
03-31 16:00
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 Jupiter Neurosciences Inc. (NASDAQ: JUNS) said it will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), on March 2–3, 2026 in Miami Beach, Florida, with its c
03-02 21:02
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Jupiter Neurosciences, Inc. announced its participation in the BIO Investment and Growth Summit 2026, where it will discuss its FDA-cleared Phase IIa Parkinson's disease program targeting neuroinflammation. The company also highlights revenue generation through Nugevia™, a consumer product built on its JOTROL™ technology platform, demonstrating strong commercial validation with 25% repeat purchase rates and 3% return rates. Jupiter's dual-path st...
03-02 13:00
Jupiter Neurosciences Amends Yorkville Financing Agreement Terms
The latest update is out from Jupiter Neurosciences, Inc. ( ($JUNS) ). On Febru...
02-21 06:31
Jupiter Neurosciences Amends Yorkville Convertible Notes to Delay Monthly Payments Until April 2026
Jupiter Neurosciences Amends Yorkville Convertible Notes to Delay Monthly Payments Until April 2026 Jupiter Neurosciences Inc. said it entered into an omnibus amendment on Feb. 20, 2026 with YA II PN, LTD (Yorkville) to modify the monthly payment terms of its amended and restated convertible promiss
02-21 06:09
BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users
BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users Jan 28 (Reuters) - Jupiter Neurosciences Inc JUNS.O : JUPITER NEUROSCIENCES INC - ANNOUNCES STRATEGIC INITIATIVE FOR GLP-1 USERS Source text: ID:nGNX8RPntl Further company coverage: JUNS.O (( Reuters.Briefs@thom
01-28 19:02
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Jupiter Neurosciences announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ product line. The initiative aims to address biological pressures on mitochondrial energy production, lean tissue preservation, and neuro-gut inflammatory balance. By leveraging mitochondrial health and cellular resilience, Nugevia™ provides a complementary solution to enhance long-term metabolic resilience an...
01-28 11:00
Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City
Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City Jupiter Neurosciences, Inc. will participate in the 3rd Annual DealFlow Discovery Conference, taking place January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, NJ. Chairman and CEO Christer Rosén
01-27 23:45
Jupiter Neurosciences Expands Equity Financing Through SEPA Advances
Jupiter Neurosciences, Inc. ( ($JUNS) ) has issued an announcement. On October ...
2025-12-24 06:49
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter Neurosciences invites investors to a webinar on January 6, 2026, to discuss its JOTROL™ platform and upcoming Phase 2a trial for Parkinson’s disease. The presentation by CEO Chister Rosén will cover the company’s dual-path strategy, including its Nugevia™ longevity products and clinical development plans. Registration and Q&A details are provided, along with information on the company’s innovative resveratrol-based technology and therapeu...
2025-12-23 13:00
